Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK ...

RAS molecular glue ERAS-0015 and pan-KRAS inhibitor ERAS-4001 Erasca will also present potential first-in-class examples of direct SMP complex inhibitors, representing a new approach to block the ...

Perion Network Ltd. , a leader in advanced technology solving for the complexities of modern advertising, announced today the filing of its annual report on Form 20-F for the fiscal year ended ...

CDR-Life today announced the expansion of its product portfolio with the nomination of CDR111 as a new clinical candidate for autoimmune diseases along with upcoming posters highlighting the company's ...

HC Wainwright issued their FY2029 earnings estimates for Erasca in a report issued on Friday, March 21st. HC Wainwright ...